Franziska Michor

CIK: 0002045159

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

RXRX

RECURSION PHARMACEUTICALS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (6 total)

RXRX
RECURSION PHARMACEUTICALS, INC.
Jun 17, 2026
Award(A)
Direct
88.4K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Jun 18, 2025
Award(A)
Direct
22K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Nov 20, 2024
Award(A)
Direct
30.6K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Nov 20, 2024
Award(A)
Direct
15.3K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Nov 20, 2024
Award(A)
Direct
17.7K shares-
RXRX
RECURSION PHARMACEUTICALS, INC.
Nov 20, 2024
Award(A)
Direct
41.4K shares-

		Type	Shares	Price		Ownership
Jun 17, 2026	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	88,424	-	$0	Direct
Jun 18, 2025	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	22,016	-	-	Direct
Nov 20, 2024	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	30,618	-	$0	Direct
Nov 20, 2024	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	15,335	-	$0	Direct
Nov 20, 2024	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	17,694	-	$0	Direct
Nov 20, 2024	RXRX RECURSION PHARMACEUTICALS, INC.	Award(A)	41,390	-	$0	Direct

1-6 of 6 transactions

About Michor Franziska

Michor Franziska (SEC CIK 0002045159) files insider reports with the SEC as Director of RECURSION PHARMACEUTICALS, INC. (RXRX).

Signal8 holds 4 ownership filings by Michor Franziska (1 Form 3, 3 Form 4), filed between Nov 22, 2024 and Jun 22, 2026. Those filings report 6 transactions, from Nov 20, 2024 to Jun 17, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Michor Franziska's filings is in SALT LAKE CITY, UT.

Recent filings by Michor Franziska

Jun 17, 2026: Grant or award of RXRX shares (Form 4, code A).
Jun 18, 2025: Grant or award of RXRX shares (Form 4, code A).
Nov 20, 2024: Grants or awards of RXRX shares (4 lines, Form 4, code A).

Other insiders filing for RECURSION PHARMACEUTICALS, INC. (RXRX)

Borgeson Blake, Director
HERSHBERG ROBERT, Director
Dar Zavain, Director
Li Dean Y, Director
Taylor Ben R, Chief Financial Officer
Khan Najat, CEO and President

How to read Form 4 transaction codes